Artios Pharma closes £25mm Series A round

15:40 EDT 22 Sep 2016 | Elsevier Business Intelligence

Newly launched cancer-focused biotech Artios Pharma Ltd. raised £25mm ($33.2mm) through its Series A round led by SV Life Sciences. Additional investors included Imperial Innovations (which took a 14.9% ownership stake with a £5.1mm investment), Merck Ventures, Arix Bioscience, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures.

Original Article: Artios Pharma closes £25mm Series A round


More From BioPortfolio on "Artios Pharma closes £25mm Series A round"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...